Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Her-2 positive mucinous carcinoma breast cancer, case report.

Garcia Hernandez I, Canavati Marcos M, Garza Montemayor M, Lopez Sotomayor D, Pineda Ochoa D, Gomez Macias GS.

Int J Surg Case Rep. 2017 Dec 26;42:242-246. doi: 10.1016/j.ijscr.2017.12.025. [Epub ahead of print]

2.

A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.

Wu G, Kim D, Kim JN, Park S, Maharjan S, Koh H, Moon K, Lee Y, Kwon HJ.

Theranostics. 2018 Jan 1;8(1):78-91. doi: 10.7150/thno.21278. eCollection 2018.

3.

Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.

Parada H Jr, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, Perou CM, Olshan AF, Troester MA.

Breast Cancer Res. 2017 Dec 11;19(1):131. doi: 10.1186/s13058-017-0914-6.

4.

Prognostic and clinicopathological significance of MUC expression in head and neck cancer: a systematic review and meta-analysis.

Lu H, Liang D, Zhu Y, Xu W, Zhou K, Liu L, Liu S, Yang W.

Oncotarget. 2017 Jul 27;8(56):96359-96372. doi: 10.18632/oncotarget.19648. eCollection 2017 Nov 10.

5.

Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V, Luther T.

Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017.

6.

Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow?

Farach-Carson MC, Lin SH, Nalty T, Satcher RL.

Front Oncol. 2017 Aug 7;7:163. doi: 10.3389/fonc.2017.00163. eCollection 2017. Review.

7.

Evaluation of peptide designing strategy against subunit reassociation in mucin 1: A steered molecular dynamics approach.

Lesitha Jeeva Kumari J, Jesu Jaya Sudan R, Sudandiradoss C.

PLoS One. 2017 Aug 17;12(8):e0183041. doi: 10.1371/journal.pone.0183041. eCollection 2017.

8.

A tumor specific antibody to aid breast cancer screening in women with dense breast tissue.

Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P.

Genes Cancer. 2017 Mar;8(3-4):536-549. doi: 10.18632/genesandcancer.134.

9.

Immunohistochemical Study of MUC1, MUC2 and MUC5AC Expression in Primary Breast Carcinoma.

Patel DS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Dhande B, Lengare P, Phegade LA, Narkhede K.

J Clin Diagn Res. 2017 Apr;11(4):EC30-EC34. doi: 10.7860/JCDR/2017/26533.9707. Epub 2017 Apr 1.

10.

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.

Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK.

PLoS One. 2017 May 2;12(5):e0176820. doi: 10.1371/journal.pone.0176820. eCollection 2017. Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179098.

11.

HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.

Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K.

Sci Rep. 2017 Mar 31;7:45768. doi: 10.1038/srep45768.

12.

Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate.

Adil Butt M, Pye H, Haidry RJ, Oukrif D, Khan SU, Puccio I, Gandy M, Reinert HW, Bloom E, Rashid M, Yahioglu G, Deonarain MP, Hamoudi R, Rodriguez-Justo M, Novelli MR, Lovat LB.

Oncotarget. 2017 Apr 11;8(15):25080-25096. doi: 10.18632/oncotarget.15340.

13.

Prognostic significance of mucin expression profiles in breast carcinoma with signet ring cells: a clinicopathological study.

Ohashi R, Hayama A, Yanagihara K, Yamashita K, Sakatani T, Takei H, Naito Z.

Diagn Pathol. 2016 Nov 15;11(1):131.

14.

MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.

Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH.

PLoS One. 2016 Oct 21;11(10):e0165031. doi: 10.1371/journal.pone.0165031. eCollection 2016.

15.

Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).

Hanson RL, Hollingsworth MA.

Biomolecules. 2016 Jul 30;6(3). pii: E34. doi: 10.3390/biom6030034. Review.

16.

Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.

Niu T, Liu Y, Zhang Y, Fu Q, Liu Z, Wang Z, Fu H, Xu J, Liu K.

Oncotarget. 2016 Aug 2;7(31):50017-50026. doi: 10.18632/oncotarget.10312.

17.

Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.

Fu H, Liu Y, Xu L, Chang Y, Zhou L, Zhang W, Yang Y, Xu J.

Medicine (Baltimore). 2016 Apr;95(17):e3225. doi: 10.1097/MD.0000000000003225.

18.

Hyper Expression of Mucin 5ac Indicates Poor Cancer Prognoses: A Meta-Analysis.

Wang X, Yan F, Shi R, Huang X, Lu S, Xu L, Ren B.

Medicine (Baltimore). 2016 Jan;95(1):e2396. doi: 10.1097/MD.0000000000002396. Review.

19.

Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study.

Menekse E, McKolanis J, Finn OJ, McAuliffe PF, Johnson R, Soran A.

Dis Markers. 2015;2015:179689. doi: 10.1155/2015/179689. Epub 2015 Nov 29.

20.

MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC.

Wang L, Zhi X, Zhu Y, Zhang Q, Wang W, Li Z, Tang J, Wang J, Wei S, Li B, Zhou J, Jiang J, Yang L, Xu H, Xu Z.

Oncotarget. 2015 Oct 20;6(32):33805-22. doi: 10.18632/oncotarget.5668.

Supplemental Content

Support Center